Teniposide sometimes effective in brain metastases from non-small cell lung cancer

In a prospective study we have treated 13 patients with brain metastases from non-small cell lung cancer with intravenous teniposide, at a dose of 150 mg/m2 on days 1, 3 and 5 given every 3 weeks on an out-patient basis. Six of the 13 patients had previously been treated for brain metastases by surg...

Full description

Saved in:
Bibliographic Details
Published in:Journal of neuro-oncology 1999-02, Vol.41 (3), p.285-289
Main Authors: BOOGERD, W, VAN DER SANDE, J. J, VAN ZANDWIJK, N
Format: Article
Language:English
Subjects:
Aged
Antineoplastic agents
Antineoplastic Agents - therapeutic use
Biological and medical sciences
Brain Neoplasms - diagnostic imaging
Brain Neoplasms - drug therapy
Brain Neoplasms - secondary
Carcinoma, Non-Small-Cell Lung - diagnostic imaging
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - secondary
Chemotherapy
Disease Progression
Female
Humans
Lung Neoplasms - drug therapy
Male
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Prospective Studies
Radiography
Teniposide - therapeutic use
Tomography, Emission-Computed
Treatment Outcome
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In a prospective study we have treated 13 patients with brain metastases from non-small cell lung cancer with intravenous teniposide, at a dose of 150 mg/m2 on days 1, 3 and 5 given every 3 weeks on an out-patient basis. Six of the 13 patients had previously been treated for brain metastases by surgery and/or radiotherapy. Seven patients experienced neurological improvement. Objective response was obtained in 3 patients (23%) (2 PR, 1 CR), and stabilization in 5 patients. Duration of response in the 3 patients with objective response was 16 weeks, 40 weeks and 80 weeks, respectively. In 2 of these patients extracranial disease responded also to teniposide therapy. Although toxicity of teniposide therapy was relatively mild, there was one patient who died as a consequence of leukopenic sepsis. The results demonstrate that teniposide has some activity in de novo as well as recurrent brain metastases from non-small cell lung cancer.
ISSN:0167-594X
1573-7373
DOI:10.1023/A:1006168507111